TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15956789
Drug: Unmodified allergen
Normalized name: catfish allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unmodified allergen extract (maximum concentration 70 mug/ml, potency 10 HEP(L)/ml)
Study: 9148259
Drug: Intact posterior
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intact posterior capsule
Study: 6206578
Drug: Radiation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation with bleomycin or vinblastine or a combination of both
Study: 6206578
Drug: Larger radiation
Normalized name: Bos taurus large intestine preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Larger radiation fraction and shorter treatment time schedule
Study: 6206578
Drug: Radiation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation with chemotherapy
Study: 28505227
Drug: Resveratrol (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol (500 mg/d) with exercise
Study: 26868063
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron sucrose (ISC)
Study: 17241249
Drug: Rifaximin 200
Normalized name: rifAXIMin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin 200 mg three times a day for 3 days
Study: 15458569
Drug: Metadate CD
Normalized name: Metadate CD
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metadate CD 20 mg
Study: 15458569
Drug: Metadate CD
Normalized name: Metadate CD
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metadate CD 40 mg
Study: 15458569
Drug: Concerta 18
Normalized name: Concerta 18mg Extended-Release Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concerta 18 mg
Study: 15458569
Drug: Concerta 36
Normalized name: Concerta 36mg Extended-Release Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concerta 36 mg
Study: 10703815
Drug: Therapeutic monoclonal
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic monoclonal antibodies (mAb)
Study: 3935343
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate (SCG) 20 mg
Study: 29289554
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg Testosterone + 50 mg Sildenafil
Study: 29289554
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg Testosterone + 10 mg Buspirone
Study: 23558873
Drug: Mifepristone 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 1200 mg every 12 hours with a high-fat meal
Study: 15713143
Drug: C. pneumoniae
Approvals — FDA: no, EMA: no, PMDA: no
Description: C. pneumoniae antibodies (IgG, IgA, IgM) measured using a solid‐phase enzyme immunoassay
Study: 15713143
Drug: C. pneumoniae
Approvals — FDA: no, EMA: no, PMDA: no
Description: C. pneumoniae antibodies (IgA, IgM)
Study: 1477848
Drug: Propranolol (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (120 mg single oral dose)
Study: 1477848
Drug: Propranolol (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (120 mg daily for 2 weeks)
Study: 1477848
Drug: Propranolol (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (240 mg daily for 2 weeks)
Study: 27787387
Drug: Saxagliptin add-on
Normalized name: Saxagliptin
DrugBank: Saxagliptin (DB06335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saxagliptin add-on therapy to continuous subcutaneous insulin infusion (CSII)
Study: 17945260
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone (IVMP) pulses (1 g/day for 5 days with an oral prednisone taper, every 4 months for 3 years, then every 6 months for 2 years)
Study: 17945260
Drug: IVMP only
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVMP only for relapses (1 g/day for 5 days with an oral prednisone taper)
Study: 15063963
Drug: Metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin plus Clomiphene Citrate (CC)
Study: 9222709
Drug: Pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 40 mg daily and clarithromycin 500 mg b.i.d. (PC)
Study: 9222709
Drug: Pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 40 mg daily, clarithromycin 500 mg b.i.d. plus amoxicillin 1 g b.i.d. (PCA)
Study: 9222709
Drug: Bismuth subcitrate
Normalized name: BISMUTH SUBCITRATE
DrugBank: Bismuth subcitrate potassium (DB09275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bismuth subcitrate 120 mg t.i.d., roxithromycin 150 mg b.i.d., metronidazole 250 mg b.i.d. plus ranitidin 300 mg (BRMR)
Study: 8236398
Drug: Intramuscular quinine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular quinine (20 mg/kg followed by 10 mg/kg every 8 h)
Study: 8236398
Drug: Intravenous quinine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous quinine (20 mg/kg followed by 10 mg/kg every 8 h)
Study: 3522030
Drug: Aluminum ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aluminum ibuprofen 400 mg
Study: 11777644
Drug: Sequential Boost
Normalized name: BOOST
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential Boost technique
Study: 31368135
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (routine blood glucose control treatment)
Study: 23061606
Drug: Intensive facial
Normalized name: sulfur
DrugBank: Octasulfur (DB09353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive facial exercises for 5 minutes after the first and third botulinum toxin-A treatment
Study: 23061606
Drug: Rest in
Normalized name: Rest Simply
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rest in a seated position for 5 minutes after the second treatment (control group)
Study: 23061606
Drug: Squeezing exercises
Normalized name: sodium bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Squeezing exercises after the second treatment (Group B)
Study: 18520606
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg dose of norfloxacin (test formulation)
Study: 18520606
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg dose of norfloxacin (reference formulation)
Study: 12391117
Drug: Albuterol (inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (inhaled bronchodilator)
Study: 12391117
Drug: Salmeterol (3-week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol (3-week treatment)
Study: 28707379
Drug: Angiolite drug-eluting
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiolite drug-eluting stent (DES)
Study: 24647459
Drug: Moderate glycemic
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate glycemic index energy (MGI) bar (47.3 g CHO)
Study: 15911704
Drug: Pyridostigmine 30
Normalized name: Pyridostigmine 30 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridostigmine 30 mg orally
Study: 12913835
Drug: High-titer (HT)
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-titer (HT) Edmonston-Zagreb measles vaccine
Study: 12913835
Drug: Standard-titer (ST)
Normalized name: ST-36
DrugBank: ST-36 (DB17275)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-titer (ST) measles vaccine
Study: 8820174
Drug: Yohimbine HCl
Normalized name: yohimbine HCl
DrugBank: Yohimbine (DB01392)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine HCl (16 mg po) administered 30 min before clonidine (2 ug/kg infused over 10 min)
Study: 8820174
Drug: Yohimbine HCl
Normalized name: yohimbine HCl
DrugBank: Yohimbine (DB01392)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine HCl (16 mg po) administered 30 min before apomorphine (0.5 mg sc)
Study: 1445740
Drug: 12 week
Normalized name: risedronate sodium 35 MG Oral Tablet, 12 Week Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 week chemotherapy regimen
Study: 1445740
Drug: 36 week
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 36 week chemotherapy regimen
Study: 6538423
Drug: Antibiotics plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics plus nimesulide 200 mg/d
Study: 25302762
Drug: Schema-therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schema-therapy
Study: 20496307
Drug: Kanamycin POS®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kanamycin POS® eye ointment (5 times a day for 7 days)
Study: 20496307
Drug: Placebo eye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo eye ointment
Study: 16098854
Drug: Paroxetine controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine controlled release (CR) 12.5 mg
Study: 16098854
Drug: Paroxetine controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine controlled release (CR) 25 mg
Study: 1221227
Drug: s.c. heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: s.c. heparin and dextran 40 (small doses)
Study: 31377851
Drug: Low sodium
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low sodium diet (LNa, 15 mg kg‐1 day‐1)
Study: 31377851
Drug: Usual diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual diet (UDiet, 46 (37-56) mg kg‐1 day‐1)
Study: 31377851
Drug: High sodium
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High sodium diet (HNa, 100 mg kg‐1 day‐1)
Study: 30235221
Drug: Daily self-report
Normalized name: DAILY SELF DISCOVERY SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily self-report questionnaires
Study: 30235221
Drug: Daily use
Normalized name: ALCOHOL 75 mL in 100 mL TOPICAL GEL [Better For Daily Use EAAE Disinfectant]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily use of PA monitors (Fitbit One™)
Study: 25986296
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy combined with meditation
Study: 15716214
Drug: Zaleplon 5
Normalized name: zaleplon 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zaleplon 5 and 10 mg nightly for 6 to 12 months
Study: 12353407
Drug: 0.5% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% ropivacaine (40 mL)
Study: 12353407
Drug: 0.5% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% ropivacaine (40 mL) plus clonidine (40 micrograms)
Study: 268268
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy (vincristine, 6-mercaptopurine, hydroxyurea, prednisone)
Study: 7128841
Drug: Ortho‐Novum 1/50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ortho‐Novum 1/50 tablets
Study: 7128841
Drug: Ortho‐Novum 1/35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ortho‐Novum 1/35 tablets
Study: 7128841
Drug: Modicon tablets
Normalized name: Medicone
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Modicon tablets
Study: 7128841
Drug: Lowest dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lowest dose product (unspecified)
Study: 28885402
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TXA); given within 3 hours after delivery; specific dosage not mentioned.
Study: 28885402
Drug: Prophylactic TXA;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic TXA; specific dosage and duration not mentioned.
Study: 17562974
Drug: Aliskiren 150
Normalized name: aliskiren 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren 150 mg daily
Study: 17562974
Drug: Aliskiren 300
Normalized name: aliskiren 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren 300 mg daily
Study: 15330493
Drug: Hyben Vital
Normalized name: Vital-Chlor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyben Vital 5 g daily
Study: 7986974
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg/day for one week
Study: 7986974
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg/day for one week followed by clarithromycin 1 g/day for 2 weeks (group B)
Study: 7986974
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg/day for one week followed by tripotassium dicitrato bismuthate 480 mg/day and clarithromycin 1 g/day for two weeks (group C)
Study: 7986974
Drug: Tripotassium dicitrato
Normalized name: Tripotassium dicitratobismuthate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tripotassium dicitrato bismuthate 480 mg/day and clarithromycin 1 g/day for two weeks (group D)
Study: 1091148
Drug: Human placental
Normalized name: Human Placental Tissue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human placental lactogen (HPL) treatment group
Study: 31814335
Drug: Enzyme Replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzyme Replacement Therapy (ERT) in CLN2 disease patients
Study: 31814335
Drug: Neurofilament light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurofilament light levels before treatment in CLN2 disease patients
Study: 24077199
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic with steroids
Study: 20687845
Drug: CDA lotion
Normalized name: 2-CdA
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CDA lotion (non-irritating hydrating lotion)
Study: 20687845
Drug: CDA lotion
Normalized name: 2-CdA
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CDA lotion (twice-daily application for 4 days)
Study: 20687845
Drug: CDA lotion
Normalized name: 2-CdA
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CDA lotion
Study: 19638365
Drug: Aggressive statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive statin administration before percutaneous coronary intervention (PCI)
Study: 15210501
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily (OD) gentamicin regimen
Study: 15210501
Drug: Multi-dose (MD)
Normalized name: VIAL ADAPTER MULTI-DOSE ALARIS #2205E
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-dose (MD) gentamicin regimen
Study: 8705090
Drug: Controlled release
Normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled release tablet of 300 mg theophylline
Study: 8705090
Drug: Intravenous dose
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dose equivalent to 131.46 mg theophylline
Study: 1324637
Drug: Daptomycin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daptomycin (3 mg/kg body weight)
Study: 1324637
Drug: Vancomycin (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin (1,000 mg)
Study: 25081651
Drug: Tiotropium 1.25
Normalized name: TIOTROPIUM 1.25MCG/ACTUAT 60D ORAL INHL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 1.25 μg
Study: 25081651
Drug: Tiotropium 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 5 μg, 1.25 μg, 2.5 μg
Study: 20947881
Drug: Clarithromycin sequential
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin sequential therapy
Study: 20947881
Drug: Levofloxacin-250 sequential
Normalized name: levofloxacin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin-250 sequential therapy
Study: 20947881
Drug: Levofloxacin-500 sequential
Normalized name: levofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin-500 sequential therapy
Study: 12548273
Drug: 3‐in‐1 nerve
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3‐in‐1 nerve block with bupivacaine plus intravenous morphine
Study: 11031221
Drug: Front-loaded regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Front-loaded regimen of clopidogrel (300 mg the first day and 75 mg/d for the next 7 days)
Study: 11031221
Drug: Standard regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard regimen of clopidogrel (75 mg/d for 8 days)
Study: 8898135
Drug: Unscrubbed, ungowned
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unscrubbed, ungowned leg holder during preparation and draping
Study: 8898135
Drug: Scrubbed and
Normalized name: Scrub-Stat
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Scrubbed and gowned leg holder during preparation and draping
Study: 8898135
Drug: General air
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: General air counts during preparation and draping
Study: 6360597
Drug: Metoclopramide 10
Normalized name: metoclopramide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 10 mg, administered orally 30 min prior to the test meal.
Study: 31977907
Drug: Moxibustion (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxibustion (twice weekly for 4 weeks at acupuncture points SP6, LR3, and CV4) plus conventional medication for 4 weeks, followed by conventional medication alone for 8 weeks.
Study: 31977907
Drug: Moxibustion plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxibustion plus conventional medication.
Study: 31977907
Drug: Conventional medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional medication alone.
Study: 30885027
Drug: Multimodal intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multimodal intervention (dexmedetomidine 1 µg/kg IV 15 minutes before anesthesia induction and bilateral transversus abdominis plane block with 0.375% ropivacaine 30 mL)
Study: 27466608
Drug: Orange maize
Normalized name: Orange
DrugBank: Orange (DB10549)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orange maize delivering 600 μg retinol equivalents (REs)/d as carotenoid plus placebo (OM)
Study: 27466608
Drug: Low‐carotenoid white
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low‐carotenoid white maize plus 600 μg REs/d as retinyl palmitate (VA)
Study: 12072066
Drug: Topical 0.1%
Normalized name: adapalene topical 0.1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.1% methylprednisolone
Study: 12072066
Drug: Topical 0.5%
Normalized name: phenol topical 0.5% topical spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.5% dexpanthenol
Study: 10500778
Drug: Quinine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine (30 mg/kg/day)
Study: 3529538
Drug: Aspirin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (25 mg/kg/day for 24 hours in four equally divided doses)
Study: 3529538
Drug: Placebo (starch,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (starch, 25 mg/kg/day for 24 hours in four equally divided doses)
Study: 31725697
Drug: Daily disposable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily disposable Acuvue Oasys (AODD)
Study: 12873325
Drug: LifeSPAN therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: LifeSPAN therapy
Study: 9533167
Drug: Antidepressant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant therapy administered once every one or two weeks or several-times-daily
Study: 9533167
Drug: Antidepressant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant therapy (general)
Study: 7999650
Drug: Epidural alfentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural alfentanil 500 micrograms in 10 mL 0.125% bupivacaine, followed by continuous infusion of alfentanil 20 micrograms/mL in 0.125% bupivacaine
Study: 7999650
Drug: Fentanyl 50
Normalized name: fentanyl 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 50 micrograms in 10 mL 0.125% bupivacaine, followed by continuous infusion of fentanyl 2 micrograms/mL in 0.125% bupivacaine
Study: 25882438
Drug: Platelet-Rich Plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-Rich Plasma (PRP) - 3 injections of 1 mL
Study: 25882438
Drug: Hyaluronic Acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic Acid (HA) - 3 injections of 1 mL
Study: 8881885
Drug: Low-energy extracorporal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-energy extracorporal shock wave therapy (3000 impulses of 0.08 mJ/mm2)
Study: 8267195
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia combined with patient‐controlled intravenous morphine (GA)
Study: 3710294
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (60 mg daily)
Study: 22068670
Drug: Control -
Normalized name: HISTAMINE 6 mg in 1 mL PERCUTANEOUS INJECTION [Positive Skin Test Control - Histamine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control - no treatment (n = 250)
Study: 17564408
Drug: Sodium oxybate
Normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium oxybate 9 g nightly
Study: 17564408
Drug: Sodium oxybate
Normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium oxybate 6 g and 9 g nightly
Study: 17564408
Drug: Sodium oxybate
Normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium oxybate (all doses)
Study: 12244893
Drug: Enteroplant (enteric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteroplant (enteric coated capsules containing 90 mg peppermint oil and 50 mg caraway oil each)
Study: 12244893
Drug: Immediate release
Normalized name: Namenda, immediate release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release formulation (5 capsules containing 36 mg peppermint oil and 20 mg caraway oil each)
Study: 12244893
Drug: Enteroplant (enteric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteroplant (enteric coated capsules)
Study: 12244893
Drug: Immediate release
Normalized name: Namenda, immediate release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release formulation
Study: 9889031
Drug: Paclitaxel 175
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 175 mg/m2 every 28 days for five cycles
Study: 9889031
Drug: Epidoxorubicin 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidoxorubicin 120 mg/m2 iv plus paclitaxel 150 mg/m2 iv every 28 days